Navitoclax (ABT-263; BCL2/BCL-XL inhibitor) was effective at targeting senescent myoblasts in DM1, similar to what was shown in an aging model38; however, the highest efficiency was achieved with the BCL-XL inhibitor A1155463. The gene discussed is BCL2L1; the disease is myotonic dystrophy type 1.